Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sugino, M.
Right arrow Articles by Shinoda, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sugino, M.
Right arrow Articles by Shinoda, K.
NEUROLOGY 1998;51:586-589
© 1998 American Academy of Neurology

A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy

M. Sugino, MD, PhD, N. Ohsawa, MD, PhD, T. Ito, MD, S. Ishida, MD, H. Yamasaki, MD, PhD, F. Kimura, MD, PhD and K. Shinoda, MD, PhD

From the First Department of Internal Medicine, Osaka Medical College, Osaka, Japan.

Address correspondence and reprint requests to Dr. Sugino, First Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-Cho, Takatsuki-City, Osaka 569-8686, Japan.

We studied the effect of IV administration of a dehydroepiandrosterone sulfate (DHEAS) preparation (200 mg/day for 8 weeks) in 11 patients with myotonic dystrophy (MyD). After DHEAS, activities of daily living improved, muscle strength increased, and myotonia decreased. Conduction block and premature beats also improved in the four patients with cardiac involvement. This pilot study may provide a rationale for a controlled study of DHEAS in MyD.

Received August 12, 1997. Accepted in final form March 19, 1998.




This article has been cited by other articles:


Home page
 NeurologyHome page
I. Penisson-Besnier, M. Devillers, R. Porcher, D. Orlikowski, V. Doppler, C. Desnuelle, X. Ferrer, M. -C.A. Bes, F. Bouhour, C. Tranchant, et al.
Dehydroepiandrosterone for myotonic dystrophy type 1
Neurology, August 5, 2008; 71(6): 407 - 412.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
F. Labrie, V. Luu-The, C. Labrie, A. Belanger, J. Simard, S.-X. Lin, and G. Pelletier
Endocrine and Intracrine Sources of Androgens in Women: Inhibition of Breast Cancer and Other Roles of Androgens and Their Precursor Dehydroepiandrosterone
Endocr. Rev., April 1, 2003; 24(2): 152 - 182.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. Arlt, F. Callies, I. Koehler, J. C. van Vlijmen, M. Fassnacht, C. J. Strasburger, M. J. Seibel, D. Huebler, M. Ernst, M. Oettel, et al.
Dehydroepiandrosterone Supplementation in Healthy Men with an Age-Related Decline of Dehydroepiandrosterone Secretion
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4686 - 4692.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
Acute respiratory failure in a middle aged woman
Postgrad. Med. J., October 1, 2001; 77(912): 669d - 669.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.